Vernalis Share Discussion Threads

[cestnous] 15/9/2009 16:29

You still here Shaid? That DataWise pratt really was as wrong as he was stupid! Looks like we're off!

[waldron] 15/9/2009 07:15

Recruitment Completed in V3381 Phase II Study (Vernalis)





TIDMVER

RNS Number : 0290Z
Vernalis PLC
15 September 2009

?
15 September 2009


Vernalis Completes Recruitment in V3381 Phase II IN-STEP Study
for Neuropathic Pain


Vernalis plc (LSE: VER) today announces it has completed patient enrolment into
the randomised phase of the V3381 (indantadol) Phase II IN-STEP study. The
study, evaluating further the safety and efficacy of indantadol in patients with
neuropathic pain due to diabetes, is being conducted at sites in the US, Canada,
UK and Czech Republic. Headline data is expected in the first half of 2010.


Neuropathic pain is a type of pain caused by damage to the nervous system. There
are numerous different causes of this damage, with diabetes, herpes (shingles)
infection and nerve trauma being some of the more common. It has been estimated
to affect between 1 and 7 per 100 individuals in the US and Europe, but is a
syndrome that is often under-diagnosed and so under-treated. It is typically
described as burning, stabbing, shooting or aching and can be very debilitating.
Traditional analgesics are often ineffective and many patients remain poorly
treated.


Studies in neuropathic pain are challenging and traditionally show a high
placebo response. The V3381 IN-STEP study was designed with an innovative
placebo run-in period which aims to minimise the confounding effects of patients
who are marked placebo-responders.
"We are delighted to have achieved this important milestone for Vernalis and to
have beaten our stated goal of full enrolment by the end of the year. By
completing recruitment ahead of target we now expect headline study results in
the first half of 2010, also earlier than previously announced" said Ian
Garland, CEO of Vernalis.


=- ends --
Enquiries:


+-------------------------------------------------+----------------------------+
| Vernalis Contacts | |
| | |
+-------------------------------------------------+----------------------------+
| Ian Garland, Chief Executive Officer | [phone] |
+-------------------------------------------------+----------------------------+
| David Mackney, Chief Financial Officer | |
| | |
+-------------------------------------------------+----------------------------+
| Brunswick Group | |
| | |
+-------------------------------------------------+----------------------------+
| Jon Coles | [phone] |
+-------------------------------------------------+----------------------------+
| Justine McIlroy | |
+-------------------------------------------------+----------------------------+


Notes to Editors


About Vernalis
Vernalis is a development stage pharmaceutical company with significant
expertise both in de novo fragment and structure-based drug discovery and
pre-clinical and clinical development. The Group has seven product candidates in
clinical development (three of which are partnered), two programmes in
pre-clinical, as well as other competitive research programmes. Our
technologies, capabilities and products are endorsed by collaborations with
leading, global pharmaceutical companies including GSK, Biogen Idec, Novartis,
Servier, Chiesi, Menarini, and Endo.




+--------------+----------------+----------------+---------+---------+---------+---------------+
| Product | Indication | Pre-Clinical | Phase | Phase | Phase | Marketing |
| | | | I | II | III | Rights |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| Priority Programmes | | | | |
+------------------------------------------------+---------+---------+---------+---------------+
| V3381 | Neuropathic | | | X | | Worldwide |
| | Pain | | | | | |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| V2006 | Parkinson's | | | X | | Biogen Idec |
| | Disease | | | | | |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| V85546 | Inflammatory | | X | | | Worldwide |
| | Disease | | | | | |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| NVP-AUY922 | Cancer | | X | | | Novartis |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| NVP-HSP990 | Cancer | | X | | | Novartis |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| V158866 | Pain | X | | | | Worldwide |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| V158411 | Cancer | X | | | | Worldwide |
| (Chk1) | | | | | | |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| Progress through partnering | | | | |
+------------------------------------------------+---------+---------+---------+---------------+
| V1512 | Parkinson's | | | X | | Worldwide |
| | Disease | | | | | (excl. |
| | | | | | | Italy) |
+--------------+----------------+----------------+---------+---------+---------+---------------+
| V10153 | Ischaemic | | | X | | Worldwide |
| | Stroke | | | | | |
+--------------+----------------+----------------+---------+---------+---------+---------------+


For further information about Vernalis, please visit www.vernalis.com


Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the
Company's current expectations regarding future events including the clinical
development and regulatory clearance of the Company's products, the Company's
ability to find partners for the development and commercialisation of its
products, as well as the Company's future capital raising activities.
Forward-looking statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a number of factors
including the success of the Company's research strategies, the applicability of
the discoveries made therein, the successful and timely completion of clinical
studies, the uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable partners for the
commercialisation and/or development of its products, as well as the achievement
of expected synergies from such transactions, the acceptance of Frova and other
products by consumers and medical professionals, the successful integration of
completed mergers and acquisitions and achievement of expected synergies from
such transactions, and the ability of the Company to identify and consummate
suitable strategic and business combination transactions.



This information is provided by RNS
The company news service from the London Stock Exchange
END

RESMGGMLKDFGLZM

[datawise] 09/9/2009 14:14

SHAID1 and cestnous... get a room ffs !!

[cestnous] 09/9/2009 08:57

Shaid

Have a look at PIM. I'm in this am. DYOR etc

Nous

[brando69] 07/9/2009 10:02

whoever it is is going to get a call from the police if they don't remove that outrageous piece of libel

[fathert] 07/9/2009 10:01

brando it will be shaid1 with a new nickname

[shaid1] 04/9/2009 10:05

100k buy went thru this morning.

[brando69] 01/9/2009 17:52

you'll hear nowt more from me

[rfinance] 01/9/2009 17:48

As far as I am concerned Shaid1 is an open target.

[brando69] 01/9/2009 16:10

i'm outta here

[tiotsoto] 01/9/2009 16:07

Mr P90

We now have this agreement with him. It's a chance to get what was once cyber's great thread back to a great thread. Let's not spoil it.

Shaid's agreeed not to bother and post on the ROS thread if we stop messing with him here and elsewhere.

Let's stick to it.

[tiotsoto] 01/9/2009 16:05

Come on Brando mate.

We now have this agreement with him. It's a chance to get what was once cyber's great thread back to a great thread. Let's not spoil it.

Shaid's agreeed not to bother and post on the ROS thread if we stop messing with him here and elsewhere.

[rfinance] 01/9/2009 14:45

brando69 - Yes, I agree with you. A wise old chinese proverb once decreed that one cannot be a carrot and a turnip (actually I think it referred to soy and rice, but you know what I mean). I'm sort of coming down on the side of turnip.

[fathert] 01/9/2009 14:01

SHAID1 it is an easy question - when did you buy at 38p

come on answer man - prove you are telling the truth




SHAID1 - 1 Sep'09 - 13:49 - 2 of 5

im in since 38p so cool lol




SHOW BRANDO WHEN YOU BOUGHT - WE ARE WAITING SHAID1